Wilma J. Teubel
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1-S Transition.
Journal: Molecular cancer therapeutics
Published: June 29, 2023
Prostate cancer androgen biosynthesis relies solely on CYP17A1 downstream metabolites.
Journal: The Journal of steroid biochemistry and molecular biology
Published: June 23, 2023
Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling.
Journal: Cells
Published: October 09, 2022
Cell Line Characteristics Predict Subsequent Resistance to Androgen Receptor-Targeted Agents (ARTA) in Preclinical Models of Prostate Cancer.
Journal: Frontiers in oncology
Published: February 16, 2022
Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Journal: The Prostate
Published: August 28, 2021
A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
Journal: The Prostate
Published: October 17, 2018
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 07, 2013
Profiling of antibody production against xenograft-released proteins by protein microarrays discovers prostate cancer markers.
Journal: Journal of proteome research
Published: December 06, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026